1,4-diazabicyclo[3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof

1. A compound of formula (I):

in which

X represents a nitrogen atom or a group of formula C—R 2 ,

P represents a group of formula C—R 3 ,

Q represents a group of formula C—R 4 ,

R represents a group of formula C—R 5 ,

W represents a group of formula C—R 6 ,

or one of the symbols P, Q, R and W represents a nitrogen atom,

R 1 represents a hydrogen atom or a (C 1 -C 6 )alkyl group,

R 2 represents a hydrogen atom or a (C 1 -C 6 )alkyl group,

R 3 and R 5 each represent, independently of each other, a hydrogen or halogen atom, or a (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, nitro, amino, trifluoromethyl or cyano group, or a group of formula —NR 7 R 8 , —NR 7 C(═O)R 8 , —NR 7 C(═O)NR 8 R 9 , —NR 7 C(═O)OR 8 , —NR 7 S(═O) 2 NR 8 R 9 , —OR 7 , —OC(═O)R 7 , —OC(═O)OR 7 , —OC(═O)ONR 7 R 8 , —OC(═O)SR 7 , —C(═O)OR 7 , —C(═O)R 7 , —C(═O)NR 7 R 8 , —SR 7 , —S(═O)R 7 , —S(═O) 2 R 7 , or —S(═O) 2 NR 7 R 8 ,

one of R 4 and R 6 is hydrogen and the other is —OS(═O) 2 R 7 , (C 6 -C 11 )aryl or (C 3 -C 12 )heteroaryl, optionally substituted with one or more groups chosen from halogen atoms and (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, nitro, amino, trifluoromethyl, and cyano groups, or groups of formula —NR 7 R 8 or —OR 7 , wherein when R 4 or R 6 represents a (C 3 -C 12 )heteroaryl, the heteroaryl is selected from the group consisting of thienyl, furyl, pyrrolyl, and pyridyl;

R 7 , R 8 and R 9 each represent, independently of each other, a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a (C 3 -C 8 )-cycloalkyl or (C 4 -C 8 )cycloalkenyl group, or a heterocycloalkyl group containing 3 to 8 atoms in the ring, or a (C 5 -C 11 )bicycloalkyl or (C 7 -C 11 )bicycloalkenyl group, a heterobicycloalkyl group containing 5 to 11 atoms in the ring, a bicycloheteroalkenyl group containing 5 to 11 atoms in the ring, or a (C 6 -C 11 )aryl or heteroaryl group containing 5 to 12 atoms in the ring,

R 7 , R 8 and R 9 may be optionally substituted, independently of each other, with a halogen atom or a (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, nitro, amino, trifluoromethyl or cyano group, or a group of formula —NR 10 R 11 , —NR 10 C(═O)R 11 , —NR 10 C(═O)NR 11 R 12 , —NR 10 C(═O)OR 11 , —NR 10 S(═O) 2 NR 11 R 12 , —OR 10 , —OC(═O)R 10 , —OC(═O)OR 10 , —OC(═O)ONR 10 R 11 , —OC(═O)SR 10 , —C(═O)OR 10 , —C(═O)R 10 , —C(═O)NR 10 R 11 , —SR 10 , —S(═O)R 10 , —S(═O) 2 R 10 , —S(═O) 2 NR 2 R 11 ,

R 10 , R 11 and R 12 each represent, independently of each other, a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a (C 3 -C 8 )-cycloalkyl or (C 4 -C 8 )cycloalkenyl group, a heterocycloalkyl group containing 3 to 8 atoms in the ring, a (C 5 -C 11 )bicycloalkyl or (C 7 -C 11 )bicycloalkenyl group, a heterobicycloalkyl group containing 5 to 11 atoms in the ring, a bicycloheteroalkenyl group containing 5 to 11 atoms in the ring, or a (C 6 -C 11 )aryl or heteroaryl group containing 5 to 12 atoms in the ring,

R 10 , R 11 and R 12 may be optionally substituted, independently of each other, with a halogen atom or a (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, nitro, amino, trifluoromethyl or cyano group, or —NR 13 R 14 , —NR 13 C(═O)R 14 , —NR 13 C(═O)NR 14 R 15 , —NR 13 C(═O)OR 14 , —NR 13 S(═O) 2 NR 14 R 15 , —OR 13 , —OC(═O)R 13 , —OC(═O)OR 13 , —OC(═O)ONR 13 R 14 , —OC(═O)SR 13 , —C(═O)OR 13 , —C(═O)R 13 , —C(═O)NR 13 R 14 , —SR 13 , —S(═O)R 13 , —S(═O) 2 R 13 , —S(═O) 2 NR 13 R 14 ,

R 13 , R 14 and R 15 each represent, independently of each other, a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a (C 3 -C 8 )-cycloalkyl or (C 4 -C 8 )cycloalkenyl group, a heterocycloalkyl group containing 3 to 8 atoms in the ring, a (C 5 -C 11 )bicycloalkyl or (C 7 -C 11 )bicycloalkenyl group, a heterobicycloalkyl group containing 5 to 11 atoms in the ring, a bicycloheteroalkenyl group containing 5 to 11 atoms in the ring or a (C 6 -C 11 )aryl or heteroaryl group containing 5 to 12 atoms in the ring, and

R 3 and R 4 , or R 4 and R 5 , or R 5 and R 6 , may together form, with the two carbon atoms that bear them, another aromatic or heteroaromatic ring containing 6 atoms in the ring, optionally substituted with 1 to 4 substituents chosen from those defined for R 7 , R 8 and R 9 ,

or an addition salt thereof.

2. The compound according to claim 1 , wherein X represents a group of formula C—R 2 .

3. The compound according to claim 2 , wherein P, Q, R and W each represent, respectively, a group of formula C—R 3 , C—R 4 , C—R 5 and C—R 6 .

4. The compound according to claim 2 , wherein one of the symbols P, Q, R and W represents a nitrogen atom.

5. The compound according to claim 1 , wherein X represents a nitrogen atom.

6. The compound according to claim 5 , wherein P, Q, R and W each represent, respectively, a group of formula C—R 3 , C—R 4 , C—R 5 and C—R 6 .

7. The compound according to claim 5 , wherein one of the symbols P, Q, R and W represents a nitrogen atom.

8. A process for preparing a compound according to claim 1 , comprising:

reacting 1,4-diazabicyclo[3.2.2]nonane with a compound of formula (III)

in which X, P, Q, R, W and R 1 are as defined in claim 1 , in the presence of a coupling agent and in a solvent, optionally after a prior step of converting the carboxylic acid function into an acid chloride function.

9. A process for preparing a compound according to claim 1 , comprising:

reacting 1,4-diazabicyclo[3.2.2]nonane with a compound of formula (IV)

in which X, P, Q, R, W and R 1 are as defined in claim 1 and Z represents a bromine or iodine atom, in the presence of carbon monoxide, a palladium catalyst and a base, in a solvent.

10. A pharmaceutical composition comprising a compound according to claim 1 and an excipient.

11. A pharmaceutical composition comprising a compound according to claim 2 and an excipient.

12. A pharmaceutical composition comprising a compound according to claim 3 and an excipient.

13. A pharmaceutical composition comprising a compound according to claim 4 and an excipient.

14. A pharmaceutical composition comprising a compound according to claim 5 and an excipient.

15. A pharmaceutical composition comprising a compound according to claim 6 and an excipient.

16. A pharmaceutical composition comprising a compound according to claim 7 and an excipient.